The report provides a detailed analysis essential for establishing a Nimodipine production plant. It encompasses all critical aspects necessary for Nimodipine production, including the cost of Nimodipine production, Nimodipine plant cost, Nimodipine production costs, and the overall Nimodipine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Nimodipine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Nimodipine is a second-generation FDA-approved drug that serves as a calcium channel blocker and is widely used in the medical industry. It is majorly utilized as an antihypertensive agent for the treatment of acute hypertensive intracerebral hemorrhage, as it lowers blood pressure. Moreover, it also finds its application in the treatment of cerebral vasospasm and cerebral infarction after subarachnoid hemorrhage due to its cerebrovascular dilating effects. Additionally, it is also employed as a treatment to relieve cerebral vasospasm, interim and early ischemic cerebrovascular migraine, and sudden deafness due to its anti-ischemic and anti-vasoconstriction effects.
The market for Nimodipine is largely driven due to its role as a calcium channel antagonist for the treatment and management of systemic hypertension, which significantly boosts its demand in the medical industry. Moreover, its usage in the treatment of ischemic cerebrovascular disease, cerebral vasospasm, migraine, and mild to moderate hypertension further enhances its demand in the medical and pharmaceutical industries. Additionally, its employment both orally and intravenously for the treatment and prevention of subarachnoid hemorrhage from ruptured intracranial aneurysm effectively promotes its demand in the pharmaceutical and healthcare industries.
Its utilization for lowering blood pressure and intracranial pressure to treat cerebrovascular disorders further accelerates its market growth. Several factors, such as the availability of raw materials (sodium acetate, etc.), cost and pricing, compliance with healthcare regulations, and maintaining quality standards, significantly influence industrial Nimodipine procurement globally. Furthermore, optimized distribution and logistics, new advances in science or technology, and powerful sustainability practices lead to variations in the requirements for procurement.
Raw Material for Nimodipine Production
According to the Nimodipine production plant project report, the major raw materials for Nimodipine production include Nitrobenzaldehyde- Methoxyethyl Acetoacetate-3-Amino Butyric Acid Isopropyl Ester-Ethanol.
Production Process of Nimodipine
The extensive Nimodipine production cost report consists of the following industrial production process:
- Production from Nitrobenzaldehyde: This method of production is initiated by the process of condensation of nitrobenzaldehyde with methoxyethyl acetoacetate in the presence of hydrochloric acid or sulfuric acid as the catalyst. Further, the obtained product is heated with 3-amino butyric acid isopropyl ester in ethanol by cyclization, which results in the formation of Nimodipine as the final product.
Nimodipine is a derivative of dihydropyridine and a member of the class of dicarboxylic acids. It is often used as a drug to treat high blood pressure due to its cerebrovascular dilating effects. The molecular formula of the compound is C21H26N2O7, and its molecular weight is 418.4 g/mol. Moreover, the compound is majorly sold under the brand name Nimotop. The melting of the compound is 125°C, and the boiling point of the compound is around 536.21°C. Additionally, it appears in the form of a white solid that is stored between 2-8°C.
